E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.

ABSTRACT:

SUBMITTER: Bewersdorf JP 

PROVIDER: S-EPMC10681888 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature